Description

Composition: Each capsule contains: Alfacalcidol 1 mcg

Auxiliary components: anhydrous citric acid, propyl gallate, alpha-tocopherol, ethanol, peanut butter.

Properties: Vitamin, regulator of calcium-phosphorus metabolism. Alfacalcidol (1α-hydroxyvitamin D3) is rapidly converted in the liver to 1,25-dihydroxyvitamin D3, an active metabolite of vitamin D (calcitriol), which acts as a regulator of calcium and phosphorus metabolism. It increases the absorption of calcium and phosphorus in the intestine, increases their reabsorption in the kidneys, restores a positive calcium balance in the treatment of calcium malabsorption syndrome and reduces the concentration of parathyroid hormone in the blood. By acting on both parts of the bone remodeling process (resorption and synthesis), alfacalcidol not only increases the mineralization of bone tissue, but also increases its elasticity by stimulating the synthesis of bone matrix proteins, bone morphogenetic proteins, bone growth factors, which helps to reduce the incidence of fractures. In elderly patients against the background of endocrine-immune dysfunction, incl. deficiency in the production of D-hormone (calcitriol), there is a decrease in total muscle mass (sarcopenia) and the appearance of muscle weakness syndrome (due to disruption of the normal functioning of the neuromuscular apparatus), which is accompanied by an increased risk of falls and the resulting injuries and fractures. A number of studies have shown a significant reduction in the incidence of falls in elderly patients with the use of alfacalcidol. Alfacalcidol stimulates the regeneration of muscle fibers, which restores lost muscle tone.

Indications:

– osteoporosis (including postmenopausal, senile, steroid);

– osteodystrophy in chronic renal failure;

– hypoparathyroidism and pseudohypoparathyroidism;

– rickets and osteomalacia associated with malnutrition or absorption;

– hypophosphatemic vitamin D-resistant rickets and osteomalacia;

– pseudo-deficient (vitamin D-dependent) rickets and osteomalacia;

– Fanconi syndrome (hereditary renal acidosis with nephrocalcinosis, late rickets and adiposogenital dystrophy);

-renal acidosis.

Dosage and administration: Assign inside. The recommended daily dose of the drug can be taken immediately for 1 dose, you can divide the dose into 2 doses. Therapy can last from 2-3 months to 1 year or more. The duration of treatment is determined by the doctor for each patient individually. Adults – 1 mcg per day. Dosage for the elderly – 0.5 mcg / day. Children under 20 kg – 0.05 mcg / kg / day. Children over 20 kg – 1 mcg per day.

Contraindications: – hypercalcemia; – hyperphosphatemia (with the exception of hyperphosphatemia in hyperparathyroidism); – hypermagnesemia; – hypervitaminosis D; -pregnancy; – lactation period (breastfeeding); – children’s age up to 3 years; – hypersensitivity to alfacalcidol and other components of the drug. With caution, the drug should be prescribed for nephrolithiasis, atherosclerosis, chronic heart failure, chronic renal failure, sarcoidosis or other granulomatosis, pulmonary tuberculosis (active form), patients with an increased risk of developing hypercalcemia, especially in the presence of urolithiasis, children over the age of 3 years.

Precautionary measures: During the use of the drug  in children and in patients with chronic renal failure, it is necessary to regularly monitor the content of calcium and phosphates (at the beginning of treatment – 1 time per week, when Cmax in the blood plasma is reached and during the entire period of treatment – every 3-5 weeks .), as well as the activity of alkaline phosphatase (in chronic renal failure – weekly control) in the blood plasma. In chronic renal failure, preliminary correction of hyperphosphatemia is required. Upon reaching normal activity of alkaline phosphatase in the blood plasma, the dose of Bonker should be reduced, which will avoid the development of hypercalcemia. At the beginning of treatment with Bonker, it is recommended to measure the calcium content, especially in conditions without significant bone damage, for example, with hypoparathyroidism and if the calcium content in the blood plasma is already elevated, as well as at later stages of treatment – if there are signs of restoration of the bone structure fabrics. The risk of developing hypercalcemia is determined by such factors as the degree of bone demineralization, the functional capacity of the kidneys and the dose of the drug.